With Heterocyclic Compound Patents (Class 514/161)
-
Publication number: 20100273746Abstract: The present invention relates to pharmaceutical formulation containing tolperisone or its pharmaceutically acceptable salts or tolperisone combined with a non-steroidal anti-inflammatory drug or their salts, gel forming macromolecule, solvent, and if required thickening agent, penetration enhancer and pH adjuvant or the mixture thereof. The invention also relates to the manufacturing process of the above mentioned pharmaceutical compositions, further the use of these formulations and the containers suitable for the dosage, which are dual compartment containers consisting of two separated chambers.Type: ApplicationFiled: December 18, 2008Publication date: October 28, 2010Inventors: Ottilia Balázs, Karoly Tihanyi, Katalin Hornok, Istvanné Kis-Varga, Mária Virágh-Hadas
-
Publication number: 20100267677Abstract: This invention relates to the control of plant pests, such as aphid and whitefly by treating plants with a compound which inhibits the plant pest's ability to overcome plant defence responses, such as piperonyl butoxide or propyl gallate, in combination with a compound which activates plant defence responses, such as cis-Jasmone or beta-amino butyric acid.Type: ApplicationFiled: May 5, 2010Publication date: October 21, 2010Applicant: Plant Bioscience LimitedInventors: Graham Moores, Georgina Bingham
-
Publication number: 20100261685Abstract: A personal care composition comprising a eutectic mixture, the eutectic mixture comprising a tertiary system, in which menthol may form part of the eutectic mixture or in the eutectic mixture comprises an antidandruff agent such as ketoconazole.Type: ApplicationFiled: November 4, 2008Publication date: October 14, 2010Inventors: Jason Shaun Burry, Richard Livesey Evans, Caroline Alexandra Hall, Ezat Khoshdel, Colina MacKay
-
Publication number: 20100260813Abstract: A rodenticidal mixture comprising a) 0.0015 to 99.89% by weight of at least one rodenticide, b) 10?8 to 95% by weight of at least one painkiller and c) 0.01 to 99.9984% by weight of at least one biocide, where the percentages by weight are based on the total of components (a), (b) and (c), is suitable for the preparation of rodenticidal bait formulations which are employed for controlling rodent pests.Type: ApplicationFiled: September 30, 2008Publication date: October 14, 2010Applicant: BASF SEInventors: Gerhard Schnabel, Michael Ishaque, Dieter Zeller, Lars Weichel, Andrej Brejc
-
Publication number: 20100261684Abstract: As many as 60% of patients who experience an acute coronary syndrome die before they even reach a hospital or other health care facilities, hence the importance of an effective treatment that the patient can self-administer at the first symptom or sign of an acute coronary syndrome. That treatment needs to act rapidly, to be easy to use, to be effective, to be safe, and readily available. The present invention describes a pharmaceutical combination containing a beta blocker agent, one or more anti-platelet agent(s) and a coronary vaso-dilator agent all included in a dose format to be taken orally or by sublingual spray to prevent myocardial infarction.Type: ApplicationFiled: April 13, 2009Publication date: October 14, 2010Inventor: Jacques Benoit
-
Publication number: 20100255045Abstract: The invention relates to a composition for photodynamic therapy. The composition of the invention, in the form of a gel or a cross-linked hydrogel, includes a chlorophyll photosensitising substance or a derivative thereof, in particular chlorophyllin optionally associated with an additional ingredient such as an alpha- or beta-hydroxy acid, a depigmentation or lightening agent, and/or an antioxidant. The invention can be used in the treatment of skin aging signs and in skin regeneration.Type: ApplicationFiled: November 27, 2008Publication date: October 7, 2010Inventor: Michèle Eymard Du Vernet
-
Publication number: 20100249078Abstract: Certain tetracyclic compounds are described, which may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).Type: ApplicationFiled: May 23, 2008Publication date: September 30, 2010Applicant: The Scrips Research InstituteInventor: Dale L. Boger
-
Publication number: 20100247534Abstract: A compound of formula I wherein m, n, A, B, D, E, G, H, Y, R1, R2, R3, R4, R5, and R8, are described herein.Type: ApplicationFiled: June 10, 2010Publication date: September 30, 2010Inventors: James A. Johnson, John Lloyd, Alexander Kover
-
Publication number: 20100247453Abstract: A composition comprising an antacid, and a local, topical anesthetic. The composition is used to relieve pain or discomfort associated with a sore throat, and therefore, the invention is also directed to a method of alleviating the pain or discomfort associated with a sore throat comprising instructing a human to orally administer the composition.Type: ApplicationFiled: May 12, 2010Publication date: September 30, 2010Inventor: Thomas L. Jones
-
Publication number: 20100249079Abstract: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of a phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.Type: ApplicationFiled: December 22, 2009Publication date: September 30, 2010Inventors: Rose A. Persichetti, Julie F. Liu, Craig E. Masse, Scott L. Harbeson
-
Publication number: 20100240620Abstract: The present application relates to novel aryl-substituted 3-cyano-5-thiazolyl- and 3-cyano-5-thiadiazolyl-1,4-dihydropyridines, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.Type: ApplicationFiled: September 8, 2007Publication date: September 23, 2010Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Lars Barfacker, Peter Kolkhof, Karl-Heinz Schlemmer, Rolf Grosser, Adam Nitsche
-
Publication number: 20100240602Abstract: The present invention provides methods and formulations for optimizing the anti-cancer and anti-HIV activities of a camptothecin drug, including camptothecin and its related analogs including 9-aminocamptothecin and 9-nitrocamptothecin. The invention involves methodologies and formulations that limit human serum albumin-mediated reduction of the anti-cancer and anti-HIV effects of the camptothecins, and the methods and formulations provide combination therapies in which binding of the camptothecin agent to human serum albumin can be modulated by the administration of a competing agent such as ibuprofen, clofibrate or clofibric acid that also binds human serum albumin. Reduced camptothecin drug binding to human serum albumin can result in elevated camptothecin free drug levels and thus improve the effectiveness of treatment regimens involving these drugs. Further agents such as methotrexate and AZT can also be used in cancer and HIV-positive patients employing camptothecin drugs.Type: ApplicationFiled: April 6, 2010Publication date: September 23, 2010Inventors: Thomas G. Burke, Daniel C. Carter
-
Publication number: 20100239552Abstract: This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable carrier.Type: ApplicationFiled: March 16, 2010Publication date: September 23, 2010Applicant: GENMEDICA THERAPEUTICS SLInventors: Eric Mayoux, Luc Marti Clauzel, Silvia Garcia-Vicente, Marta Serrano Munoz, Antonio Zorzano Olarte, Alec Mian
-
Publication number: 20100239520Abstract: The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.Type: ApplicationFiled: August 22, 2007Publication date: September 23, 2010Inventors: Natalie Dales, Zaihui Zhang
-
Publication number: 20100233116Abstract: The present invention provides heterocyclic derivatives hat modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.Type: ApplicationFiled: August 13, 2007Publication date: September 16, 2010Inventors: Natalie Dales, Julia Fonarev, Jianmin Fu, Rajender Kamboj, Vishnumurthy Kodumuru, Shifeng Liu, Natalia Pokrovskaia, Vandna Raina, Shaoyi Sun, Zaihui Zhang
-
Publication number: 20100226918Abstract: The present invention relates to compounds of the formula I, in which R1; R2; R3; R4; R5; R6; R7; R8; R9; R10; R11; R12; R13; A; B, D and E have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: ApplicationFiled: December 16, 2009Publication date: September 9, 2010Applicant: SANOFI-AVENTISInventors: Otmar KLINGLER, Joerg CZECH, Werngard CZECHTIZKY, Tilo WEISS, Melitta JUST
-
Publication number: 20100210605Abstract: Compositions comprising 5-amino-2-hydroxybenzoic acid (5-amino salicylic acid, mesalamine) and a reducing sugar, e.g., lactose, undergo the Maillard and other chemical reactions and produce, in the case of lactose, a degradant 5-[2-formyl-5-(hydroxymethyl)-1H-pyrrol-1-yl]-2-hydroxybenzoic acid. Inventors have developed means to contain and/or reduce the formation of degradants of 5-amino-2-hydroxybenzoic acid.Type: ApplicationFiled: April 28, 2010Publication date: August 19, 2010Applicant: WARNER CHILCOTT COMPANY, LLCInventors: Matthew John Kaczanowski, Thomas Daniel Williams, Kurt Franklin Trombley, Nancy Lee Redman-Furey
-
Publication number: 20100210606Abstract: The invention features a method for treating an immunoinflammatory administering a compound of formula (I), e.g., ibudilast or KC-764, alone or in combination with a corticosteroid, tetra-substituted pyrimidopyrimidine, or other compound. The invention also features pharmaceutical compositions including the combination above for the treatment or prevention of an immunoinflammatory disorder.Type: ApplicationFiled: May 3, 2010Publication date: August 19, 2010Inventors: Edward Roydon Jost-Price, Palaniyandi Manivasakam, Brendan Smith, Michael S. Slavonic, Benjamin A. Auspitz
-
Publication number: 20100210604Abstract: A formulation is provided that includes a volume of an aqueous multivalent physiological ion solution compatible with cerebrospinal fluid containing at least one divalent cation of magnesium or calcium, and at least one anion of carbonate or phosphate, and having a pH between 6.5 and 8.0. A zwitterionic therapeutic agent other than baclofen is dissolved the solution to achieve higher concentration or ease of solution and/or storage relative to therapeutic saline solutions of the same agent. A process of delivering a zwitterionic therapeutic agent into a subject is provided that includes dissolving a therapeutic amount of the zwitterionic therapeutic agent in a volume of artificial cerebrospinal fluid to form a stable formulation. The solution is then administered to the subject using an intrathecal pump.Type: ApplicationFiled: June 13, 2008Publication date: August 19, 2010Inventor: Jay M. Meythaler
-
Publication number: 20100203132Abstract: A combination therapy for cardiovascular diseases, in particular essential hypertension, pulmonary hypertension and/or congestive heart failure, involving administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system, and at least one AT1 receptor antagonist.Type: ApplicationFiled: April 21, 2010Publication date: August 12, 2010Applicant: Solvay Pharmaceuticals GmbHInventors: Dieter Ziegler, Klaus Witte, Matthias Straub, Yvan Fischer, Dirk Thormaehlen, Dagmar Hoeltje
-
Publication number: 20100196387Abstract: In the present invention there are disclosed new derivatives of dianhydrohexite mononitrate corresponding to formula (I), tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof: as well as pharmaceutical compositions comprising these compounds and uses thereof.Type: ApplicationFiled: April 6, 2010Publication date: August 5, 2010Applicant: Lacer, S.A.Inventors: Jose Repolles Moliner, Eduardo Salas Perez-Rasilla, Francisco Pubill Coy
-
Publication number: 20100189797Abstract: Oral antidepressant formulation comprising a means for controlling the release of the pharmaceutically acceptable antidepressant active agent selected from the group consisting of SSRI agents, SNRIs (serotonin noradrenaline reuptake inhibitors), CRF antagonists, NK1 antagonists, NK2 antagonists, NK3 antagonists and combinations thereof, with respect to the release of the compound selected from the group consisting of acetylsalicylic acid, salts and esters of acetylsalicylic acid, diaspirin, and mixtures thereof.Type: ApplicationFiled: December 22, 2009Publication date: July 29, 2010Inventors: Julien MENDLEWICZ, Philippe Kriwin, Roland Powis De Tenbossche
-
Publication number: 20100189669Abstract: Personal care compositions containing an active selected from the group consisting of phlorogine, phlorgine BG, deoxyArbutin, sucrose dilaurate, bakuchiol, pyrenoine, millet, arlatone dioic acid, cinnamic acid, ferulic acid, achromaxyl, methyl nicotinamide, oil soluble licorice extract, folic acid, undecylenic acid, zinc undecylenate, L-tryptophan, thiamine HCl, hexylresorcinol, lipidami red vine, dragosine, methyl gentisate, inositol, symdiol 68, laminaine, their salts, their derivatives, their precursors, and/or combinations thereof. Methods for regulating the condition of mammalian keratinous tissue by topically applying the personal care compositions are also provided.Type: ApplicationFiled: January 25, 2010Publication date: July 29, 2010Inventor: Tomohiro Hakozaki
-
Patent number: 7763597Abstract: There is provided pharmaceutically-acceptable acid addition salts of compounds of formula (I), wherein R1 represents C1-2 alkyl substituted by one or more fluoro substituents; R2 represents C1-2 alkyl; and n represents 0, 1 or 2, which salts are useful as prodrugs of competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required.Type: GrantFiled: August 16, 2007Date of Patent: July 27, 2010Assignee: AstraZeneca ABInventors: Matti Ahlqvist, Martin Bohlin, Tord Inghardt, Anita Lundblad, Carl-Gustaf Sigfridsson
-
Publication number: 20100184728Abstract: The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. In one embodiment, a composition suitable for administration as an enema comprises an effective amount of 5-ASA and a steroid such as budesonide or hydrocortisone. The subject invention also concerns compositions formulated for oral administration. In one embodiment, a composition comprises alpha-lipoic acid, and/or N-acetyl-L-cysteine (N-A-C), and/or L-glutamine. The alpha-lipoic acid can be racemic alpha-lipoic acid, R-lipoic acid, or R-dihydro-lipoic acid. Methods of the invention include administration of compounds or compositions of the invention.Type: ApplicationFiled: June 13, 2008Publication date: July 22, 2010Applicant: THERAPEUTIC RESEARCH LLCInventor: Jay Pravda
-
Publication number: 20100184727Abstract: A muscarinic receptor antagonist is useful for the treatment or prevention of a condition associated with excess sebum production or excretion.Type: ApplicationFiled: June 7, 2007Publication date: July 22, 2010Applicant: SUMMIT (CAMBRIDGE) LIMITEDInventors: Alan Geoffrey Roach, Paul Goldsmith
-
Publication number: 20100184729Abstract: The present invention relates to novel pharmaceutical compositions comprising at least one direct thrombin inhibitor and at least one additional active compound selected from the groups consisting of platelet inhibitors, low molecular weight heparins (LMWH) and heparinoids as well as unfractionated heparin, factor Xa inhibitors, combined thrombin/factor Xa inhibitors, fibrinogen receptor antagonists (glycolprotein IIb/IIa antagonists) and Vitamin K antagonists, optionally together with one or more pharmaceutically acceptable excipients or carriers for the treatment of thrombosis.Type: ApplicationFiled: March 19, 2010Publication date: July 22, 2010Applicant: Boehringer Ingelheim International GmbHInventors: Paul A. Reilly, James C. Gilbert, Thomas H. Mueller
-
Publication number: 20100178334Abstract: The present invention relates to an oral pharmaceutical preparation for use in the prevention and/or reduction of gastrointestinal complications associated with the use of acetyl salicylic acid. The present preparation comprises a fixed oral dosage form comprising a proton pump inhibitor in combination with acetyl salicylic acid. Furthermore, the present invention refers to a method for the manufacture thereof and the use thereof in medicine. The present invention also relates to a specific combination comprising esomeprazole, or an alkaline salt thereof or a hydrated form of any one of them, and acetyl salicylic acid for use as a medicament for the prevention of thromboembolic vascular events, such as myocardial infarction or stroke, and for the prevention and/or reduction of gastrointestinal complications associated with the use of acetyl salicylic acid.Type: ApplicationFiled: November 28, 2006Publication date: July 15, 2010Inventors: Dick Johansson, Lena Nilsson, Lars-Erik Svedberg
-
Publication number: 20100179095Abstract: This invention relates to the use of folates for producing a pharmaceutical preparation suitable for the prevention and treatment of inflammation and of diseases associated with inflammation, particularly for influencing the inflammation markers C-reactive protein (CRP) and serum amyloid A protein (SAA). The clinical areas of application are all anomalies of the CRP and SAA levels.Type: ApplicationFiled: January 29, 2010Publication date: July 15, 2010Inventors: Thomas MUELLER, Rudolf Moser, Martin Ulmann
-
Publication number: 20100174222Abstract: Disclosed is a system and method for treatment of skin disorders. More particularly, the disclosed invention is directed toward the reduction of acne and acne related bacteria using low-intensity light therapy. In an illustrative embodiment, skin containing acne bacteria is treated with a series of pulses of light from a light emitting diode. The LED has a dominant emissive wavelength of about 660 nm and an energy output of about 4 m W. The acne bacteria-containing tissue is exposed to pulses from the light source about 100 times for about 250 milliseconds per pulse, with an interpulse interval of about 100 milliseconds.Type: ApplicationFiled: August 31, 2009Publication date: July 8, 2010Inventor: David H. McDaniel
-
Publication number: 20100166839Abstract: Non-peptidic renin inhibitors nitroderivatives of general formula (I): A1-(Xa—ONO2)j ??(I) having wider pharmacological activity and enhanced tolerability. They can be employed for treating or preventing cardiovascular, renal and chronic liver diseases, inflammatory processes and metabolic syndrome.Type: ApplicationFiled: March 1, 2007Publication date: July 1, 2010Applicant: Nicox S.AInventors: Nicoletta Almirante, Stefano Biondi, Ennio Ongini
-
Publication number: 20100160266Abstract: A pleuromutilin in the form of a salt with salicylic acid, azelaic acid, sebacic acid or 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid.Type: ApplicationFiled: June 14, 2006Publication date: June 24, 2010Applicant: NABRIVA THERAPEUTICS FORSCHUNGS GMBHInventor: Gerd Ascher
-
Publication number: 20100150899Abstract: The present invention relates to new pyrazolinone scavengers of free radicals, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 10, 2009Publication date: June 17, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20100150913Abstract: The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention also relates to methods for screening compounds and compositions useful for inhibiting or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.Type: ApplicationFiled: November 8, 2007Publication date: June 17, 2010Applicant: The Rockefeller UniversityInventors: Robert Blue, Barry S. Coller
-
Publication number: 20100144610Abstract: An aspect of the present invention provides for a medicament including a solution containing pleconaril or a pharmaceutically acceptable salt thereof, wherein at least one solvent including the solution is a pleconaril-dissolving hydrofluorocarbon.Type: ApplicationFiled: February 17, 2010Publication date: June 10, 2010Inventors: Saeed M. Chaudhry, Julianne Berry, Joel A. Sequeira
-
Publication number: 20100143341Abstract: The present invention relates to novel pharmaceutical compositions of general formula (I) comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.Type: ApplicationFiled: June 21, 2006Publication date: June 10, 2010Applicant: DEVELOGEN AKTIENGESELLSCHAFTInventors: Steven Taylor, Stephen Murfin, Thomas Stephen Coulter, Stefan Jakel, Babette Aicher, Arndt-Rene Kelter, Joachim Kraemer, Christian Kirchhoff, Andreas Scheel, Julian Woelcke
-
Publication number: 20100130453Abstract: This invention relates to the use of folates for the prevention and/or treatment of cardiovascular diseases, such as atherosclerosis, and in particular for modulating endothelial nitric oxide synthase (eNOS). The invention further relates to pharmaceutical preparations consisting of said folates and a pharmaceutically acceptable carrier, optionally in combination with other pharmaceutically active agents, as well as therapeutic methods using said folates or pharmaceutical preparations thereof.Type: ApplicationFiled: January 15, 2010Publication date: May 27, 2010Inventors: Charalambos Antoniades, Cheerag Shirodaria, Keith M. Channon, Rudolf Moser
-
Publication number: 20100112048Abstract: The present invention relates to a synergistic combination for preventing the onset and/or progression of dementia or Alzheimer's disease in individuals at increased risk thereof for example because of family history, genetic factors, and/or environmental factors. This combination comprises synergistically effective amounts of vitamin C, vitamin E, DHA and at least one NSAID such as ibuprofen.Type: ApplicationFiled: July 19, 2006Publication date: May 6, 2010Inventor: Majid Fotuhi
-
Patent number: 7691832Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention contains N-acetylcysteine disposed in a pharmaceutically acceptable carrier for oral or rectal delivery for treating such inflammatory bowel diseases by topical application within the colon.Type: GrantFiled: February 2, 2006Date of Patent: April 6, 2010Assignee: The Board of Regents of the University of OklahomaInventor: Richard F. Harty
-
Publication number: 20100080846Abstract: The present invention provides pharmaceutical formulations of dipyridamole and acetylsalicylic acid, methods of making thereof, and methods of using thereof.Type: ApplicationFiled: September 25, 2009Publication date: April 1, 2010Inventors: Avshalom Ben-Menachem, Ilan Zalit
-
Publication number: 20100075931Abstract: Certain oxazole ketone compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).Type: ApplicationFiled: September 7, 2007Publication date: March 25, 2010Applicant: THE SCRIPPS RESEARCH INSTITUTEInventor: Dale L. Boger
-
Publication number: 20100068269Abstract: A pharmaceutical dosage form for treating or preventing cardiovascular events comprises therapeutic amounts of: a ?-adrenergic receptor antagonist, a diuretic, or both; a cholesterol-lowering agent; an inhibitor of the renin-angiotensin system; and aspirin.Type: ApplicationFiled: November 19, 2009Publication date: March 18, 2010Applicants: DR. REDDY'S LABORATORIES LIMITED, DR. REDDY'S LABORATORIES, INC.Inventors: Badal Kumar Sasmal, Billa Praveen Reddy, Vijay Dinanathji Nasare, Mailatur Sivaraman Mohan
-
Publication number: 20100048518Abstract: The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition comprises a combination of tenatoprazole and one or more anti-inflammatory agents selected from non-steroid anti-inflammatory agents and cyclooxygenase-2 inhibitors. The invention is suitable for the treatment of painful and inflammatory manifestations.Type: ApplicationFiled: October 27, 2009Publication date: February 25, 2010Applicants: Sidem Pharma, Mitsubishi Pharma CorporationInventors: Francois Schutze, Suzy Charbit, Hervé Ficheux, Michel Homerin, Alain Taccoen, Nathalie Taccoen, Yoshio Inaba
-
Publication number: 20100035849Abstract: The present invention provides novel methylenedioxy phenolic compounds and their derivatives, methods of making them and methods of using them to treat or prevent cardiovascular disease, vascular disease and/or inflammatory disease, as well as Type I and Type II Diabetes and Dyslipidemia patients at risk for hypertension, stroke, cardiovascular and renal disease.Type: ApplicationFiled: August 5, 2009Publication date: February 11, 2010Applicants: OHIO STATE UNIVERSITY RESEARCH FOUNDATION, INVASC THERAPEUTICS, INC.Inventors: Sampath Parthasarathy, Sanjay Rajagopalan, Desikan Rajagopal
-
Publication number: 20100035848Abstract: A method for managing or treating an inflammatory, erosive, dyspeptic or reflux disorder of the proximal digestive tract of a subject comprises administering to the subject a therapeutically effective amount of an ACE2 inhibitor. A therapeutic combination, useful to treat any disease or condition in which an NSAID is indicated, comprises an NSAID in an anti-inflammatory, analgesic or antipyretic effective amount and a gastroprotective agent that comprises an ACE2 inhibitor in an amount effective to protect mucosal surfaces of the proximal digestive tract from erosion or ulceration induced by the NSAID.Type: ApplicationFiled: March 10, 2009Publication date: February 11, 2010Inventors: Stephen Richard Donahue, Michael David Jacobson, John Joseph Byrnes, III, Luz-Maria Guzman, Thomas Michael Barnes, Robert Mark Coopersmith, Scott Edward Malstrom
-
Publication number: 20100028447Abstract: The present invention generally relates to pharmaceutical compositions for the intranasal, buccal, or sublingual administration of metanicotine analogs.Type: ApplicationFiled: January 22, 2008Publication date: February 4, 2010Applicant: TARGACEPT, INC.Inventors: Sharon Rae Letchworth, Merouane Bencherif, Gary Maurice Dull, David Moore, John W. James
-
Publication number: 20100021571Abstract: This invention provides anti-acne kits that are useful for treating acne, especially severe cases of acne. The anti-acne kits include a vasoconstrictor and an anti-acne agent, and optionally one or more of a a skin lightening therapeutic, a sealing layer, a skin cleanser, an astringent, a skin penetration enhancer, a sunscreen, and nutritional supplements that promote healing of acne lesions. This invention also provides methods for treating acne using a vasoconstrictor in conjunction with an anti-acne agent.Type: ApplicationFiled: March 30, 2006Publication date: January 28, 2010Applicant: Revance Therapeutics, Inc.Inventors: Jacob M. Waugh, Jae Hoon Lee
-
Publication number: 20100022484Abstract: The present application relates to novel 4-chromenonyl-1,4-dihydropyridines, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.Type: ApplicationFiled: July 12, 2006Publication date: January 28, 2010Inventors: Alexander Kuhl, Peter Kolkhof, Heike Heckroth, Karl-Heinz Schlemmer, Ingo Flamme, Santiago Gigueroa Perez, Heike Gielen-Haertwig, Rolf Grosser, Jens-Kerim Ergüden, Dieter Lang
-
Publication number: 20100015220Abstract: Provided are pharmaceutical compositions and methods for preventing or reducing niacin-induced flushing comprising an aspirin component and a niacin component having different release profiles. Also provided are methods and compositions for preventing or reducing niacin-induced flushing comprising niacin, aspirin and a lipid-lowering drug other than niacin.Type: ApplicationFiled: May 20, 2009Publication date: January 21, 2010Inventors: John R. WETTERAU, Lingyu Zhu, Robert A. Scott, Constance H. Keyserling, Jean-Louis H. Dasseux, Daniela Carmen Oniciu, Pierre Autant, Roger Kravtzoff, Catherine Castan, Hervé Guillard
-
Publication number: 20100008927Abstract: The present invention relates to the use of 6-(benzyl-amino)-2(S)-[[1-(hydroxymethyl) propyl]amino]-9-isopropylpurine) or at least one of its pharmaceutical acceptable salts for manufacturing a medication intended for the prevention and/or treatment of neurological diseases, in particular associated with neurological lesions.Type: ApplicationFiled: March 30, 2007Publication date: January 14, 2010Applicant: NEUROKIN INMEDInventors: Serge Timsit, Bénédicte Menn, Laurent Meijer